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ABSTRACT 
Objective: To assess knowledge, attitudes, and preferences regarding inhaled therapy among Spanish community pharmacists.  
Methods: An 11-item questionnaire was developed and distributed to community pharmacists throughout the country. Data collected included 
demographics, the source of knowledge of inhaler use, known and preferred devices, steps for correct use of metered-dose (pMDI) and dry-powder 
(DPI) inhalers, important variables when prescribing an inhaler device, patient education, and checking inhaler technique. 
Results: Of a total of 3000 questionnaires delivered, 1722 (57.4%) were returned. The most common source of knowledge was the package insert 
(46.9%) followed by personal experience (33.3%). DiskusTM and TurbuhalerTM
Conclusion: In spite of the increasing involvement of Spanish community pharmacists in patients’ care, their knowledge of inhaler use and attitudes 
towards inhaled therapy needs to improve, so that they can provide better patient education. 
 were the best-known devices (96.4% and 93.4%), and DPIs the preferred 
inhalers. Although more than half of the surveyed pharmacists were aware of the most important step for correct inhalation with pMDI and DPI, only 
18% identified the correct answer ‘Patient’s preference’ as the most important variable when prescribing an inhaler device. Most of the respondents had 
inadequate knowledge of inhaled therapies. Statistically, significant differences were found according to geographical areas. Moreover, the mean score 
on inhaled therapy with one knowledge source was higher than for those with none (P<0.05). Additionally, patient education was poor.  
Keywords: Inhaler devices, Inhalation techniques, Community pharmacist, Misuse of inhalers 




Drug delivery by inhalation allows faster onset of action and causes 
fewer and milder adverse events as compared with systemic 
delivery routes [1]. Although inhaled therapy can be utilized in a 
variety of diseases [2], its main use is in obstructive respiratory 
diseases. Inhaled therapy is the recommended treatment of choice in 
the clinical guidelines for asthma [3, 4] and chronic obstructive 
pulmonary disease (COPD) [5, 6]. Many inhalation devices are 
currently available, thus allowing customized prescriptions. 
However, this wide range of devices also represents a drawback 
because healthcare providers should know the different types and 
the differences between them. 
Moreover, benefits of inhaled therapy can be limited by inadequate 
inhalation maneuvering and inhaler handling [7, 8]. The main problem 
with inhalers is the inhalation technique especially with pressurized 
metered-dose inhalers (pMDIs) [4]. Even though the newest dry-
powder inhalers (DPIs) can be easier to use than older devices [9], 
patient education is paramount. For that reason, the main guidelines 
on asthma and COPD, such as GINA (Global Initiative for Asthma) [3], 
GEMA (Spanish Guide for Asthma Management) [4], and GOLD (Global 
Initiative for Chronic Obstructive Lung Disease) [6] recommend 
patient education and training in all stages of the disease. Training and 
follow-up in the use of inhalation devices are regarded as the most 
important steps in education programs. Similarly, national societies 
such as the Spanish Society of Pneumology and Thoracic Surgery 
(SEPAR) [10] and international societies such as the European 
Respiratory Society (ERS) and the International Society of Aerosol in 
Medicine (ISAM) [11] have developed guidelines and consensus 
reports for the use of inhaled therapy.  
Community pharmacists have an important role in education and 
training of patients with obstructive respiratory diseases [3, 12]. As 
shown in a COPD case finding a program in community pharmacists 
as a new strategy to reduce COPD underdiagnosis [13], community 
pharmacists were able to select and assessed patients using a 
questionnaire and spirometric testing. Also, when pharmacists have 
been trained, results of their intervention in educational programs 
were similar to those obtained by physicians and/or nurses [3, 4]. 
Pharmacists working in community pharmacies should be included 
in interdisciplinary teams to educate patients and thus obtain the 
maximum benefit from inhaled therapy [14-18]. 
The OPTIM Pharmacy Study is a project aimed to assess knowledge, 
attitudes, and preferences regarding inhaled therapy among health 
care providers in Spain. In two previous national surveys regarding 
the level of knowledge and attitudes of both practicing physicians 
from specialties that frequently prescribe inhaler devices [19] and 
nurses working with respiratory patients using inhaler devices [20], 
knowledge of inhalers and inhalation techniques remains poor in 
Spain. The present study was designed to assess knowledge about 
inhalation therapy in the third group of professionals involved in 
respiratory patients’ care: pharmacists, specifically those working in 
community pharmacies. 
MATERIALS AND METHODS 
Design and study population 
This was a cross-sectional survey study, the objective of which was to 
assess the level of knowledge, attitudes, and preferences related to 
inhaled therapy among community pharmacists. Between May and 
November 2014, a questionnaire specifically designed for the study 
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was distributed to community pharmacists throughout Spain by sales 
representatives of a pharmaceutical company (Chiesi España).  
Questionnaire 
An 11-item questionnaire (table 1) was developed based on 
those used in the prior surveys among Spanish physicians [19] 
and nurses [20]. Moreover, responses to items 6 to 8 were 
scored as 0 (incorrect response) or 1 (correct response).  
The sum of the scores allowed respondents to be classified 
according to their general knowledge of inhaled therapy: null or 
no knowledge (0 points), poor (1 point), limited (2 points), and 
adequate (3 points). 
 
Table 1: Administered questionnaire 
1. Sex Male/Female 
2. Age (years) 



















4. Your knowledge of inhaler use comes mainly from:  
Attendance at meetings, courses, or workshops organized by scientific societies 
Attendance at meetings, courses, or workshops organized by pharmaceutical companies 
Reading articles or specialized books  
Reading the device leaflet  
Directly from personal clinical experience and common sense 
5. Please mark 




























































6. In your opinion, the most important step for correct pMDI inhalation is:  
  
To shake the device before inhalation  
To exhale deeply before inhalation  
To fire the device during inhalation 
To inhale deeply and forcefully 
To inhale slowly and progressively 
7. In your opinion, the most important step for correct DPI inhalation is:  
To shake the device before inhalation  
To exhale before inhalation  
To fire the device during inhalation 
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To breath in deeply and forcefully 
To inhale slowly and progressively 
8. When prescribing an inhaler device, which of the following variables do you consider the most important?  
Disease to be treated 
Patient’s preferences 
Patient’s age 
Patient’s experience with a specific device 
Patient’s cultural level 






10. At your pharmacy, who trains the patients in the inhalation technique of the prescribed device?  
You, personally 
A pharmacy assistant 
Either a pharmacy assistant or you, it depends on 
Nobody. They only receive written information 
Nobody. No written information is provided 
11. Do you check at least once a year the inhalation technique used by your patients treated with inhaled therapy? 
Yes 
No 
If you answered No:  
I think that they should already know how to do this 
I do not think that it is necessary 
DPI, dry-powder inhaler; pMDI, metered-dose inhaler, a
 
Statistical analysis 
Categorical variables were expressed as frequencies and percentages, 
and continuous variables as mean and 95% confidence interval (CI). 
When the questionnaires were not fully completed, the response rates 
for each incomplete item were calculated on valid responses. Descriptive 
statistics were gathered and the results were expressed as a number of 
respondents, percentages, and valid percentages. Additionally, scores 
were analyzed using contingency tables, chi-square test and analysis of 
variance (ANOVA) to assess general knowledge of inhaled therapy. 
Statistical significance was set at a P value<0.05. Analyses were 
performed using Statistical Package for the Social Sciences (SPSS Inc., 
Chicago, IL, USA) version 19 for Windows. 
RESULTS 
Of a total of 3000 questionnaires delivered during the survey period, 
1722 (57.4%) were returned.  
Demographic characteristics 
There were 747 men and 949 women (missing data, n = 26), with a 
mean age of 46.6 y (95% CI 45.7 to 47.5) (range 20-81 y) (missing 
data for age, n = 53). 
Percentages were estimated based on the number of valid answers.  
Most pharmacies were located in towns with a population of over 
5000: 1389 pharmacies vs. 298 in towns with a lower population. 
This question was not answered in 35 questionnaires. Thus, the 
valid percentages were 82.3% and 17.7%, respectively. 
As far as the Spanish geographical area where pharmacists were 
working, and excluding the 13 questionnaires with missing data, 
numbers and valid percentages were as follows: 318 (18.6%) in the 
Northern area, 410 (24.0%) in the Central area, 343 (20.1%) in the 
Southern area, 609 (35.6%) in the Eastern area, and 29 (1.7%) in the 
Canary Islands, Ceuta and Melilla. This geographical allocation is a 
grouping of autonomous communities and cities corresponding to 
the commercial areas of Chiesi España.  
Knowledge sources 
The most important source of knowledge was the package insert of 
the devices, followed by the pharmacist’s personal experience 
(table 2). The answer and percentage totals in table 2 are higher 
than 1722 and 100%, respectively, because respondents were able 
to choose more than one answer. By a number of knowledge 
sources, 56 respondents (3.3%) declared no source, 1309 (76.0%) 
only one source and 357 (20.7%) more than one. This last group 
included two sources reported by 240 respondents (13.9%), three 
sources reported by 92 respondents (5.3), four sources reported 
by 17 respondents (1.0%), and five sources reported by 8 
respondents (0.5%). 
 
Table 2: Knowledge sources 
Item  No. (%) 
4. Your knowledge of inhaler use comes mainly from:   
Attendance at meetings, courses, or workshops organized by scientific societies 196 (11.4) 
Attendance at meetings, courses, or workshops organized by pharmaceutical companies 328 (19.0) 
Reading articles or specialized books  268 (15.6) 
Reading the package insert 808 (46.9) 
Directly from personal clinical experience and common sense 573 (33.3) 
 
Known and preferred inhalers 
Among inhalation devices available in Spain, DiskusTM (AccuhalerTM 
in Spain) was the best known, followed by TurbuhalerTM, while 
TwisthalerTM
By number of inhalers known, 245 respondents (14.2%) were 
familiar with the 13 proposed devices. When the numbers of known 
inhalers were grouped, 22 respondents (1.3%) did not mark any 
device; 634 (36.8%) knew from 1 to 6; 549 (31.9%) from 7 to 9; and 
517 (30%) knew ten or more inhalers. Nexthaler
 was the least known (table 3). The sums of answers 
and percentages in table 2 are higher than 1722 and 100%, 
respectively, because item 5a also allowed multiple responses. This 
question was not answered by 22 respondents. 
TM was the 
preferred inhaler, followed by AccuhalerTM, while TwisthalerTM was 
the least preferred (table 4). 
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Table 3: Knowledge of inhalers 
Item No. (%) 
5a. Which device do you know?   
AccuhalerTM 1660 (96.4)   
AerolizerTM 804 (46.7)   
BreezhalerTM 956 (55.5)   
pMDI 1297 (75.3) 
pMDI with inhalation chamber  1116 (64.8) 
pMDI with ModuliteTM 894 (51.9) system 
EasyhalerTM 703 (40.8)   
HandihalerTM 828 (48.1)   
NexthalerTM 1304 (75.7)   
NovolizerTM 664 (38.6)   
RespimatTM 1008 (58.5)   
TurbuhalerTM 1608 (93.4)   
TwisthalerTM 562 (32.6)   
pMDI, pressurized metered-dose inhaler 
 
Table 4: Preference for one inhaler 
Item No. (%) 
5b. Which device do you prefer?   
AccuhalerTM 368 (25.7)   
AerolizerTM 22 (1.5)   
BreezhalerTM 26 (1.8)   
pMDI  75 (5.2) 
pMDI with inhalation chamber  125 (8.7) 
pMDI with ModuliteTM 46 (3.2) system 
EasyhalerTM 15 (1.0)   
HandihalerTM 27 (1.9)   
NexthalerTM 385 (26.9)   
NovolizerTM 9 (0.6)   
RespimatTM 55 (3.8)   
TurbuhalerTM 274 (19.1)   
TwisthalerTM 6 (0.6)   
pMDI, pressurized metered-dose inhaler 
 
By type of preferred device, 1132 respondents (79.0%) answered 
DPIs, 246 (17.2%) pMDIs and 55 (3.8%) RespimatTM
More than half of the respondents answered correctly that the most 
important step for a correct inhalation technique using pMDI devices 
is firing the device during inhalation (table 5). In contrast, 77 
respondents did not answer this question or marked more than one 
option.  
. A further 289 
respondents (16.8% of questionnaires returned) did not answer the 
question or marked more than one preferred device. 
Knowledge of inhalation techniques and prescription 
Similarly, more than half of the respondents stated correctly that 
the most important step for correct PDI inhalation is to breathe in 
deeply and forcefully (table 4). Fifty-three respondents did not 
answer this question or marked more than one option. 
 
Table 5: Knowledge of inhalation techniques and prescription 
Item No. (%) 
6. The most important step for correct pMDI inhalation is:   
To shake the device before inhalation  152 (9.2) 
To exhale deeply before inhalation  195 (11.9) 
To fire the device during inhalation 912 (55.4) a 
To inhale deeply and forcefully 174 (10.6) 
To inhale slowly and progressively 212 (12.9) 
7. The most important step for correct DPI inhalation is:   
To shake the device before inhalation  37 (2.2) 
To exhale deeply before inhalation  259 (15.5) 
To fire the device during inhalation 179 (10.7) 
To inhale deeply and forcefully 929 (55.7) a 
To inhale slowly and progressively 265 (15.9) 
8. When prescribing an inhaler device, which of the following variables do you consider the most important?  
Disease to be treated 438 (26.6) 
Patient’s preferences 304 (18.5) a 
Patient’s age 335 (20.3) 
Patient’s experience with a specific device 478 (29.0) 
Patient’s cultural level 92 (5.6) 
DPI, dry-powder inhaler; pMDI, pressurized metered-dose inhaler. aCorrect answer. 
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Regarding the most important variable when prescribing an inhaler, 
the most frequent answer was “Patient’s experience with specific 
devices” (table 4), but this answer was incorrect. Roughly 18.5% of 
pharmacists surveyed answered correctly “Patient’s preferences”. As 
in previous items, some respondents (n = 75) did not answer or 
marked more than one option. 
Patient education 
Most of the respondents reported that, when dispensing the inhaler, 
they only sometimes or rarely assessed the patient’s skills with the 
device (table 6). Ten respondents (0.6%) did not answer this 
question.
 
Table 6: Patient education 
Item No. (%) 
9. When dispensing the device, do you assess the patient skill with its use?   
Always 133 (7.8) 
Usually 313 (18.3) 
Sometimes 673 (39.3) 
Rarely 450 (26.3) 
Never 143 (8.4) 
10. At your pharmacy, who trains the patients in the inhalation technique?   
A pharmacist 208 (12.2) 
A pharmacy assistant 122 (7.2) 
Either a pharmacist or a pharmacy assistant 812 (47.6) 
Nobody. We asked them if they have been trained 564 (33.1) 
11. At your pharmacy, do you check the inhalation technique of your customers?  
Yes 459 (26.7) 
No 1263 (73.3) 
If you do not, why not?  
I think that they should already know how to do this 857 (71.7) 
I do not think that it is necessary 338 (28.3) 
 
With regard to the training of patients in inhalation technique, the 
most frequent answer was “Either a pharmacist or a pharmacy 
assistant”. However, one-third of respondents stated that they do 
not train them and that they ask the patients if they have been 
educated by their doctor or nurse (table 6). Sixteen respondents 
(0.9%) did not answer.  
Finally, only about a quarter of the respondents checked the 
inhalation technique of their patients. Among those who did not 
check the inhalation technique, most respondents considered that 
the patients should already be familiar with it (table 6) and 68 
respondents (5.4% of those who did not check the inhalation 
technique) did not answer. 
Analysis of inhaled therapy knowledge  
Most of the respondents had an inadequate or limited knowledge of 
inhaled therapy, while only a small percentage had an adequate 
knowledge (table 7). 
 
Table 7: Score distribution of inhaled therapy knowledge 
Knowledge level Frequency % 
Null or no knowledge (0 points) 301 17.5 
Inadequate (1 point)  667 38.7 
Limited (2 points) 650 37.7 
Adequate (3 points) 104 6.0 
Results showed no statistically significant differences according to sex (chi-square test, P = 0.96), age of respondents (Kruskall Wallis test, P = 0.30), 
and population size of the town where their pharmacy office was located (data not shown) (chi-square test, P = 0.29). However, differences among 
geographical areas were statistically significant, with the lowest scores in the Central area, the Canary Islands, and Ceuta and Melilla (chi-square 
test, P = 0.002).  
 
The relationship between the knowledge source and the number of 
known devices was assessed using two contingency tables (data not 
shown). An ANOVA test identified statistically significant differences 
(P<0.05) between scores of pharmacists with no knowledge source 
and those with one source. Differences were not statistically 
significant for those with more than one knowledge source. In 
contrast, the number of known devices did not account for 
statistically significant differences (data not shown). 
DISCUSSION 
Community pharmacists are increasingly involved in the healthcare of 
patients with chronic diseases [21, 22], including patients with chronic 
respiratory conditions [23]. It has been shown that pharmaceutical 
care of patients with obstructive respiratory diseases improves 
medication adherence [24-27] and achieves a better use of inhalers 
[26, 28-30] and control of the disease [31, 32]. In a randomized 
controlled study to investigate the effect of a simple educational 
intervention concerning DPI technique delivered by community 
pharmacists to patients with asthma, a simple educational 
intervention taking only 2.5 min and targeting inhaler technique was 
feasible for delivery by community pharmacists and resulted in 
improved clinical and humanistic outcomes for patients with asthma 
[33]. Also, in a comparison of the effectiveness of four different 
instructional interventions in training proper inhaler technique, a 
2-minute pharmacist counseling session was more effective than 
to read a metered dose inhaler (MDI) package insert pamphlet or 
to watch a Centers for Disease Control and Prevention video or 
YouTube video demonstrating MDI technique [34]. 
The present survey among Spanish community pharmacists showed 
interesting findings. Firstly, knowledge regarding inhaled therapy 
was inadequate or limited in 76.4% of the study sample, and only 
6% of community pharmacists had an adequate knowledge. 
Secondly, patient education was unsatisfactory. The skills of patients 
when dispensing an inhaler was checked only sometimes or almost 
never in 65.6% of the cases. Also, training in correct inhaler 
technique was not provided by 33.1% of respondents and the 
inhalation technique was not checked by 73.3%.  
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Other studies, although with a different methodology, also found 
the poor knowledge of inhaled therapy among community 
pharmacists. In a sample of Spanish community pharmacists who 
were asked to demonstrate the inhalation technique with three 
inhalers, the mean percentage of correct steps was 47.4% with a 
pMDI, 55.9% with TurbuhalerTM and 49.4% with AccuhalerTM 
[35]. In a study carried out in Jordan in a convenience sample of 
31 pharmacists who attended an educational workshop, at the 
initial assessment few pharmacists demonstrated correct 
technique (TurbuhalerTM 13%, DiskusTM6%) but 2 y after 
training, pharmacists in the intervention group showed 
significantly better inhaler technique than pharmacists in the 
control group (P<0.05) for TurbuhalerTM and DiskusTM (83% 
vs.11%; 75% vs.11%, respectively) [36]. In a study that evaluated 
the most problematic steps in the use of DiskusTM and TurbuhalerTM
However, different studies have shown that educational 
interventions improve community pharmacists’ competence in 
inhaled therapy. In a study in which community pharmacists were 
asked to demonstrate the proper steps in the actuation sequences of 
Diskus
 
among pharmacists from to countries, Jordan and Australia, few 
professionals in either country demonstrated correct technique for 
step 3 (exhale to residual volume) or step 4 (exhale away from the 
device) [37]. In a French study, among the 57 pharmacists who gave 
a demonstration of the use of inhaler devices, 16.3% showed all the 
steps in the use of a metered dose aerosol [38]. 
TM and TurbuhalerTM and then received an instructional 
session on the proper inhalation technique, the mean change 
between baseline and post-instruction percentage scores for 
DiskusTM and TurbuhalerTM
More than half of the respondents correctly identified the most 
important step for using a pMDI or DPI inhaler (items 6 and 7 of the 
questionnaire). However, 81.5% of those surveyed failed to respond 
correctly to question 8, which asked about the most important 
variable when prescribing an inhaler device (the correct answer 
“Patients’ preferences” was selected by only 18.5% of pharmacists). 
There were no differences in knowledge of inhaled therapy 
according to sex, age and size of the population of the area. However, 
scores by geographical area differed. This result may indicate that 
pharmacist education requires different approaches according to a 
geographical area.  
 were 22.6±18.7% and 17.1±15.4%, 
respectively [39]. Therefore, a single instructional session can 
dramatically improve a community pharmacist’s ability to 
demonstrate the correct method of actuation [39]. As previously 
mentioned, the sample of 31 pharmacists in the study carried out in 
Jordan, also showed significant increases in the correct use of the 
inhaler technique 2 y after training as compared to pharmacists 
assigned to the non-intervention group [36]. Similarly, skills in the 
use of pMDI, breath-actuated pMDI and DPI improved significantly 
(P < 0.001) after 10 y of continuing pharmaceutical education [38, 
40]. Some efforts have been made to improve Spanish community 
pharmacists’ knowledge inhaled therapy knowledge, but our survey 
shows that more educational initiatives are needed. 
The number of devices known did not modify the scores relating to 
knowledge of inhaled therapy. By contrast, the number of 
knowledge sources did: pharmacists with one knowledge source had 
higher scores than their colleagues with none (p<0.05) or more than 
one source (p non-significant). Package insert and personal 
experience were the most frequent knowledge sources, but that does 
not necessarily mean that all respondents with one source used 
either one or the other. It may perhaps be useful to analyze scores by 
knowledge source. Nonetheless, this result highlighted the 
importance of being informed about inhalation devices. In 
agreement with our findings, in a Canadian study [41], the only 
knowledge source for 33% of community pharmacists was the 
package insert, while 40% had received instruction from a 
pharmaceutical representative. The authors concluded that 
community pharmacists’ knowledge of inhalation devices was 
proportional to the length of time the device had been available. 
Patient education has been assessed in studies with simulated 
patients. In a study carried out in the United States that evaluated a 
pharmacist's practice in patient education when dispensing an MDI 
to an investigator posing as a patient, only 13% of pharmacists 
offered initially to provide information regarding correct technique, 
and when asked for instruction on MDI usage, 53% of pharmacists 
offered information [42]. Also, in a simulated patient study 
performed in 160 Australian community pharmacies in 2009, only 
24% of pharmacists provided counseling on inhalation technique 
[43]. Furthermore, in a recent survey in a sample of 77 Australian 
community pharmacists, 54% reported that they demonstrated the 
inhalation technique for new inhaled medicines and 35% checked 
for written asthma self-management plan possession. Although 65% 
of pharmacists reported confidence in communication skills, most 
pharmacists were not confident in setting short-/long-term goals 
with the patient and career for managing asthma at home [44]. This 
study concludes that Pharmacists need more appropriate 
continuing education programs that can translate into improved 
pediatric asthma self-management practices and thus improved 
asthma outcomes in children. In fact, these and many other studies 
have addressed the effects of education and assessment by 
community pharmacists of patients with asthma or COPD by 
community pharmacists [15, 26, 30-33,45-47], including children 
with asthma [58] and elderly subjects [59]. Moreover, in 
community pharmacies from different countries several initiatives 
to improve inhaler use have been implemented, such as the 
Australian Inhaler Technique Labels [50], the Pharmacy Asthma 
Management Service (PAMS) [53], and the Danish Inhaler 
Technique Assessment Service (ITAS) [60]. 
CONCLUSION 
Despite Spanish community pharmacists’ increasing involvement of 
in-patient care, their knowledge of, and attitudes towards, inhaled 
therapy needs to improve in order to provide better patient 
education.  
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